公开(公告)号：KR101487238B1

公开(公告)日：2015-01-29

申请号：KR1020080107486

申请日：2008-10-31

Applicant: 조선대학교산학협력단

Inventor： 유진철 ,  김태성 ,  김승현

IPC: A61K31/40 ,  C12N1/12 ,  A61P35/00

Abstract: 본 발명은 나르제니신(nargenicin)을 유효 성분으로 하는 항암제 조성물에 관한 것이다. 본 발명의 조성물은 특히, 전골수구성 백혈병 치료용 항암제로도 효과적으로 사용될 수 있다.
나르제니신, 백혈병, 항암제

公开(公告)号：KR100807196B1

公开(公告)日：2008-02-28

申请号：KR1020060128398

申请日：2006-12-15

Applicant: 조선대학교산학협력단

Inventor： 유진철 ,  김태성 ,  최진호 ,  김승현 ,  이효정 ,  김성준 ,  하정완

IPC: A61K35/618 ,  A61K9/00

CPC classification number: A61K35/618 ,  A61K9/0053

Abstract: An extract of Scapharca broughtonii is provided to be able to inhibit the induction of promyelocytic leukemia and auto-immune diseases, thereby being widely utilized as an anti-cancer agent or for treating various immune-diseases. A pharmaceutical composition for treating promyelocytic leukemia comprises an alcohol extract of Scapharca broughtonii and a pharmaceutically acceptable carrier. A method for preparing an alcohol fraction of the Scapharca broughtonii comprises the steps of: (a) after removing muscle from the Scapharca broughtonii and washing it with ice-cooled salt, freeze-drying it; (b) after finely cutting the frozen muscle and dipping it in a mixture solvent of ethanol and water in a volumetric ratio of 60:40 at room temperature of 3-10 days, evaporating an ethanol-aqueous solution obtained by removing remaining solid phase materials therefrom through centrifugation under reduced pressure to eliminate the ethanol; (c) adding activated carbon to the aqueous solution and agitating it; (d) separating the activated carbon from the aqueous solution through filtration and washing it with distilled water; (e) respectively eluting effective ingredients from the activated carbon using an 80% aqueous solution of acetone and 100% ethanol; (f) putting two eluents together and drying it under reduced pressure; (g) subjecting the dried material to a stepwise elution using 100% ethyl acetate, 100% ethanol and 100% methanol to fractionate; and (h) respectively concentrating the obtained ethanol fraction and methanol fraction and respectively purifying them through a silica-gel chromatography.

Abstract translation: 提供石斛提取物以能够抑制早幼粒细胞白血病和自身免疫疾病的诱导，从而被广泛用作抗癌剂或用于治疗各种免疫疾病。 一种用于治疗早幼粒细胞白血病的药物组合物，其包含石菖蒲的酒精提取物和药学上可接受的载体。 用于制备石菖蒲酒精馏分的方法包括以下步骤：（a）从玻璃after after中除去肌肉后，用冰冷却的盐洗涤，冷冻干燥; （b）精细切割冷冻肌肉后，在3-10天的室温下将体积比为60:40的乙醇和水的混合溶剂浸渍，蒸发除去剩余的固相物质得到的乙醇 - 水溶液 通过在减压下离心以除去乙醇; （c）向水溶液中加入活性炭并搅拌; （d）通过过滤从水溶液中分离活性炭并用蒸馏水洗涤; （e）使用80％丙酮和100％乙醇水溶液分别从活性炭洗脱有效成分; （f）将两种洗脱液放在一起，减压干燥; （g）使用100％乙酸乙酯，100％乙醇和100％甲醇对干燥的物质进行逐步洗脱以分馏; 和（h）分别浓缩得到的乙醇级分和甲醇级分，并通过硅胶色谱法分别纯化。

公开(公告)号：KR1020090093773A

公开(公告)日：2009-09-02

申请号：KR1020080107486

申请日：2008-10-31

Applicant: 조선대학교산학협력단

Inventor： 유진철 ,  김태성 ,  김승현

IPC: A61K31/40 ,  C12N1/12 ,  A61P35/00

CPC classification number: A61K31/4025 ,  A61K31/047 ,  A61K31/203 ,  A61K2300/00 ,  Y10S514/908

Abstract: An anticancer composition containing a nargenicin as an active ingredient is provided to effectively induce the differentiation of leukemia cell and use as an therapeutic agent for acute promyelocytic leukemia. A composition for treating promyelocytic leukemia comprises mixture of nargenicin, 1,25-dihydroxy vitamin D3(1,25-(OH)2D3) or all-trans retinoic acid (ATRA) and pharmaceutically acceptable carrier. The nargenicin is produced by soil-isolated Nocarida sp. CS682. Promyelocytic leukemia is caused by the undifferentiation of promyelocyte.

Abstract translation: 提供含有纳高质蛋白作为活性成分的抗癌组合物，以有效诱导白血病细胞的分化，并用作急性早幼粒细胞白血病的治疗剂。 用于治疗早幼粒细胞白血病的组合物包括纳高蛋白，1,25-二羟基维生素D3（1,25-（OH）2D3）或全反式视黄酸（ATRA）和药学上可接受的载体的混合物。 Nargenicin是由土壤分离的Nocarida sp。 CS682。 早幼粒细胞白血病是由前髓细胞的未分化引起的。

公开(公告)号：KR1020110049967A

公开(公告)日：2011-05-13

申请号：KR1020090106758

申请日：2009-11-06

Applicant: 조선대학교산학협력단

Inventor： 유진철 ,  김태성 ,  김승현 ,  이효정 ,  조승식

IPC: A61K36/258 ,  A61P35/02 ,  A61K31/203 ,  A61K31/59

CPC classification number: A61K36/258 ,  A61K2236/33 ,  Y10S514/908

Abstract: PURPOSE: An anticancer drug composition containing ginseng extract is provided to differenetiate undifferentiated promyelocytic blood cells and to be used as a therapeutic agent for promyelocytic leukemia. CONSTITUTION: An anticancer composition contains methanol extract of ginseng, 1,25-dihydroxy vitamin D_3(1,25-(OH)_2D_3) or all-transfretinoic acid mixture and carrier. A therapeutic agent for promyeolocytic leukemia contains the ginseng methanol extract as an active ingredient and pharmaceutically acceptable carrier. The final concentration of 1,25-(OH)_2D_3, retinoic acid, and nargenicin is 5 nM, 50 nM, and 200 mM, respectively.

Abstract translation: 目的：提供含有人参提取物的抗癌药物组合物，以分化未分化的前髓细胞血细胞，并用作早幼粒细胞白血病的治疗剂。 构成：抗癌组合物含有人参甲醇提取物，1,25-二羟基维生素D_3（1,25-（OH）_2D_3）或全转氨酸的混合物和载体。 前列腺细胞性白血病的治疗剂含有人参甲醇提取物作为活性成分和药学上可接受的载体。 1,25-（OH）_2D_3，视黄酸和Nargenicin的最终浓度分别为5nM，50nM和200mM。